Loading...
Loading...
Compugen
CGEN announced today that it is significantly increasing its
Pipeline Program activities in the field of immuno-oncology. The primary
purpose of the increase is to allow research and preclinical activities
for a larger number of checkpoint target and product candidates for
cancer immunotherapy to move forward in parallel. Additional objectives
include the establishment of a biomarker discovery program for certain
of the Company's checkpoint product candidates and the acceleration of
experimental validation efforts for the recently disclosed antibody drug
conjugate (ADC) target candidates for oncology.
The significant increase in immuno-oncology activities during 2014 will
impact both the target research and validation activities performed in
Israel
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in